Benchmark Co. analyst Robert Wasserman has maintained their bullish stance on TECH stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Robert Wasserman has given his Buy rating due to a combination of factors indicating strong future growth prospects for Bio-Techne. The company reported better-than-expected financial results for the second quarter of 2025, with revenues and earnings surpassing estimates. This growth was driven by robust performance in both the Protein Sciences Segment and the Diagnostic & Spatial Biology unit, which defied industry trends of declining growth in the diagnostics sector.
Additionally, the company’s expanding customer base in Cell & Gene Therapy and the successful launch of new instruments like the COMET contributed to its positive outlook. Revenue growth in North America and Europe also bolstered the company’s position. Wasserman maintains a Buy rating with a $95 price target, highlighting the potential for approximately 30% growth in share price based on projected revenues for the calendar year 2025.
Wasserman covers the Healthcare sector, focusing on stocks such as Ligand Pharma, ImmunoPrecise Antibodies, and Emergent Biosolutions. According to TipRanks, Wasserman has an average return of 6.4% and a 42.96% success rate on recommended stocks.
In another report released today, Robert W. Baird also maintained a Buy rating on the stock with a $88.00 price target.